FI954853A - 1,5-bentsodiatsepiinijohdannaisia, joilla on CCK-antagonistinen tai agonistinen aktiivisuus - Google Patents

1,5-bentsodiatsepiinijohdannaisia, joilla on CCK-antagonistinen tai agonistinen aktiivisuus Download PDF

Info

Publication number
FI954853A
FI954853A FI954853A FI954853A FI954853A FI 954853 A FI954853 A FI 954853A FI 954853 A FI954853 A FI 954853A FI 954853 A FI954853 A FI 954853A FI 954853 A FI954853 A FI 954853A
Authority
FI
Finland
Prior art keywords
agonist activity
benzodiazepine derivatives
cck antagonist
cck
antagonist
Prior art date
Application number
FI954853A
Other languages
English (en)
Swedish (sv)
Other versions
FI954853A0 (fi
Inventor
Elizabeth Ellen Sugg
Christopher Joseph Aquino
Jerzy Ryszard Szewczyk
Harry Finch
Robin Arthur Ellis Carr
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of FI954853A publication Critical patent/FI954853A/fi
Publication of FI954853A0 publication Critical patent/FI954853A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
FI954853A 1993-04-15 1995-10-12 1,5-bentsodiatsepiinijohdannaisia, joilla on CCK-antagonistinen tai agonistinen aktiivisuus FI954853A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin
PCT/EP1994/001131 WO1994024149A1 (en) 1993-04-15 1994-04-14 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity

Publications (2)

Publication Number Publication Date
FI954853A true FI954853A (fi) 1995-10-12
FI954853A0 FI954853A0 (fi) 1995-10-12

Family

ID=10733915

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954853A FI954853A0 (fi) 1993-04-15 1995-10-12 1,5-bentsodiatsepiinijohdannaisia, joilla on CCK-antagonistinen tai agonistinen aktiivisuus

Country Status (34)

Country Link
US (2) US5646140A (fi)
EP (1) EP0694039B1 (fi)
JP (1) JP3406317B2 (fi)
KR (1) KR100364948B1 (fi)
CN (1) CN1058487C (fi)
AP (2) AP462A (fi)
AT (1) ATE198894T1 (fi)
AU (1) AU681139B2 (fi)
CA (1) CA2158973C (fi)
CZ (1) CZ286695B6 (fi)
DE (1) DE69426624T2 (fi)
DK (1) DK0694039T3 (fi)
EC (1) ECSP941066A (fi)
ES (1) ES2154674T3 (fi)
FI (1) FI954853A0 (fi)
GB (1) GB9307833D0 (fi)
GR (1) GR3035641T3 (fi)
HK (1) HK1003943A1 (fi)
HU (1) HU223467B1 (fi)
IL (2) IL109315A0 (fi)
IS (2) IS4148A (fi)
MY (2) MY112237A (fi)
NO (1) NO311133B1 (fi)
NZ (1) NZ265272A (fi)
OA (1) OA10355A (fi)
PE (2) PE50994A1 (fi)
PH (1) PH30897A (fi)
PL (1) PL178790B1 (fi)
PT (1) PT694039E (fi)
RU (1) RU2135486C1 (fi)
SK (1) SK281211B6 (fi)
TW (1) TW487703B (fi)
WO (1) WO1994024149A1 (fi)
ZA (2) ZA942570B (fi)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE214056T1 (de) * 1993-12-28 2002-03-15 Shionogi & Co Benzodiazepinderivate
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
ES2135722T3 (es) * 1994-04-14 1999-11-01 Glaxo Wellcome Inc 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
EP0755394A1 (en) * 1994-04-15 1997-01-29 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
IL124808A0 (en) 1995-12-11 1999-01-26 New England Medical Center Inc Assay for and uses of peptide hormone receptor ligands
JP3999819B2 (ja) * 1996-12-10 2007-10-31 ゼリア新薬工業株式会社 1,5―ベンゾジアセピン誘導体
ZA983170B (en) 1997-04-15 1999-10-15 Csir Pharmaceutical compositions having appetite suppressant activity.
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
MXPA04008073A (es) * 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
CN1950374A (zh) * 2004-05-25 2007-04-18 辉瑞产品公司 四氮杂苯并[e]甘菊环衍生物及其类似物
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
MX2009002018A (es) * 2006-08-25 2009-03-05 Abbott Lab Derivados de indazol que inhiben vanilloide-1 potencial de receptor pasajero (trpv1) y usos de los mismos.
WO2008079683A2 (en) * 2006-12-20 2008-07-03 Abbott Laboratories N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
EP2323989A4 (en) * 2008-03-20 2011-06-22 Abbott Lab METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
AU2014348191B2 (en) 2013-11-18 2019-03-28 Forma Therapeutics Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
HUE060259T2 (hu) 2015-07-22 2023-02-28 Enanta Pharm Inc Benzodiazepin származékok mint RSV-gátlók
CA3012832A1 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. N-azepinyl-carboxamide inhibitors of receptor-interacting protein kinase1
RS63203B1 (sr) 2016-12-09 2022-06-30 Denali Therapeutics Inc Jedinjenja korisna kao inhibitori ripk1
CA3065368A1 (en) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) * 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
AU2018339068B2 (en) 2017-09-29 2022-12-15 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
KR20210138684A (ko) 2019-03-18 2021-11-19 이난타 파마슈티칼스, 인코포레이티드 Rsv 억제제로서의 벤조디아제핀 유도체
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
ES2135722T3 (es) * 1994-04-14 1999-11-01 Glaxo Wellcome Inc 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.

Also Published As

Publication number Publication date
AU681139B2 (en) 1997-08-21
IL109315A0 (en) 1994-07-31
IL109316A (en) 1999-03-12
PL311084A1 (en) 1996-02-05
ECSP941066A (es) 1994-11-16
NO954090D0 (no) 1995-10-13
KR100364948B1 (ko) 2003-03-29
PH30897A (en) 1997-12-23
TW487703B (en) 2002-05-21
PE50594A1 (es) 1995-01-06
OA10355A (en) 2001-10-19
GR3035641T3 (en) 2001-06-29
IS4147A (is) 1994-10-16
CA2158973C (en) 2006-06-06
IL109316A0 (en) 1994-07-31
DE69426624D1 (de) 2001-03-01
AU6567694A (en) 1994-11-08
PT694039E (pt) 2001-06-29
CZ286695B6 (en) 2000-06-14
FI954853A0 (fi) 1995-10-12
ZA942571B (en) 1994-11-11
CN1120843A (zh) 1996-04-17
WO1994024149A1 (en) 1994-10-27
MY131569A (en) 2007-08-30
EP0694039B1 (en) 2001-01-24
US5646140A (en) 1997-07-08
NO954090L (no) 1995-12-13
CN1058487C (zh) 2000-11-15
EP0694039A1 (en) 1996-01-31
RU2135486C1 (ru) 1999-08-27
SK281211B6 (sk) 2001-01-18
AP9400635A0 (en) 1994-04-30
PE50994A1 (es) 1995-01-06
DE69426624T2 (de) 2001-06-21
HUT74102A (en) 1996-11-28
NZ265272A (en) 1997-07-27
CA2158973A1 (en) 1994-10-27
AP462A (en) 1996-02-19
US5585376A (en) 1996-12-17
ATE198894T1 (de) 2001-02-15
GB9307833D0 (en) 1993-06-02
IS4148A (is) 1994-10-16
NO311133B1 (no) 2001-10-15
SK125395A3 (en) 1996-06-05
JP3406317B2 (ja) 2003-05-12
ZA942570B (en) 1994-11-11
JPH08508744A (ja) 1996-09-17
CZ267595A3 (en) 1996-04-17
AP512A (en) 1996-07-29
HK1003943A1 (en) 1998-11-13
DK0694039T3 (da) 2001-05-21
PL178790B1 (pl) 2000-06-30
ES2154674T3 (es) 2001-04-16
AP9400634A0 (en) 1994-04-30
HU223467B1 (hu) 2004-07-28
HU9502978D0 (en) 1995-12-28
MY112237A (en) 2001-05-31

Similar Documents

Publication Publication Date Title
FI954853A (fi) 1,5-bentsodiatsepiinijohdannaisia, joilla on CCK-antagonistinen tai agonistinen aktiivisuus
TR199600001A2 (tr) Estrojen agonistleri / antagonistleri.
IS5860A (is) 4,4-bíarýlpíperidín afleiður með ópíóíð viðtaka virkni
FI963539A (fi) (4,4-difluoribut-3-enyylitio)-substituoituja heterosyklisiä tai karbosyklisiä rengasyhdisteitä, joilla on tuhoeläinmyrkkyvaikutusta
DE69736711D1 (de) Substituierte 6,5-heterobicyclische-derivate
NO990892L (no) Substituerte 6,6-hetero-bicykliske derivater
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
ATE171167T1 (de) 1,5-benzodiazepin-derivate verwendbar als cck oder gastrin antagonisten
FI970823A (fi) Uusia peptidijohdannaisia, joilla esiintyy delta-opioidireseptoreihin kohdistuvia antagonistisia vaikutuksia tai samanaikaisia my-agonistisia/delta-antagonistisia vaikutuksia
MA23504A1 (fr) Derives de la 1,5 benzodiazepine
FI954852A (fi) 1,5-bentsodiatsepiinijohdannaisia, joilla on CCK- ja/tai gastriiniantagonistinen aktiivisuus
EP0662964A1 (en) HETEROCYCLIC AMINES AS CALMODULIN ANTAGONISTE.
FI962319A (fi) C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivisuutta
DE9310323U1 (de) Arretierung für schwenkbare Konstruktionsteile
AU7228994A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
KR930018183U (ko) 도금용 개량 안착구
FR2710560B1 (fr) Aérographe à démultiplication multiple.
KR930018182U (ko) 도금용 개량 안착구
FI93303C (fi) Kääntöalusta istuimiin tai muuhun käyttöön